Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Abuse Deterrent Opioids: FDA Offers Tier-Based Testing Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance provides roadmap for testing generic solid oral opioid products; FDA's Califf notes difficulty in conducting post-market studies.


Related Content

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review
Abuse-Deterrent Opioids: FDA Advocates Joint Brand-Generic Development Plan
FDA's Latest Opioid Move Aims To 'Reset The Conversation' On Benzodiazepine Combo
Watson’s Bupropion XL Undone By Outlier Patient, Bankrupt CRO


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts